An observational study in Diphtheria, Tetanus and Pertussis, sponsored by LG Life Sciences. Status unknown. Open to participants aged 6 Weeks and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-07.
Sponsored by LG Life Sciences (part of LG Chem) · Observational
A multicenter, observational study to evaluate the safety of Euforvac-Hib vaccine for active primary immunization against diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenza type B in infants.
Euforvac-Hib vaccine manufactured by LG Life science in Korea, but it's not marketed in Korea. It is distributed to UN agencies in diverse countries. Thus, WHO recommended LG Life Science to conduct the safety study for assessing the vaccine safety if Euforvac-Hib is prequalified.
The objectives of this safety study are to identify any problems and questionable issues likely to emerge from the actual use of Euforvac-Hib vaccine after launching in the market.
270 studies on the registry are indexed under Diphtheria; 17 are open to participants now.
This study's planned enrollment of 3,000 is above the median of 970 across 24 observational studies indexed under Diphtheria.
Browse Diphtheria studies →LG Life Sciences is the lead sponsor of 78 studies on the registry; none are open to participants now.
First submitted before LG Life Sciences became part of LG Chem.
Counted across the registry records on this site, refreshed daily.
Infant from 6 weeks of age.who is given this vaccine for active primary immunization against diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenza type B
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adverse event
Time frame: up to 12 weeks after vaccination
No study locations are listed for this record.
This study is status unknown, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.